HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid

structure given in first source
Also Known As:
1,4,7,10-DOTA; 1,4,7,10-tetraazacyclododecane--N,N',N'',N'''-tetraacetic acid; 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane; 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetryl)tetraacetic acid; CuDOTA; DOTA; DOTA acid; tetraxetan; 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
Networked: 1086 relevant articles (85 outcomes, 251 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Chen, Xiaoyuan: 27 articles (01/2021 - 01/2004)
2. Tolmachev, Vladimir: 25 articles (10/2020 - 02/2007)
3. Orlova, Anna: 24 articles (10/2020 - 02/2007)
4. Krenning, Eric P: 23 articles (03/2022 - 04/2002)
5. de Jong, Marion: 23 articles (12/2021 - 04/2003)
6. Boerman, Otto C: 17 articles (12/2019 - 11/2002)
7. Cheng, Zhen: 15 articles (01/2020 - 02/2002)
8. Miao, Yubin: 14 articles (02/2022 - 02/2002)
9. Maecke, Helmut R: 14 articles (07/2020 - 01/2005)
10. Schibli, Roger: 12 articles (01/2022 - 07/2011)

Related Diseases

1. Neoplasms (Cancer)
2. Neoplasm Metastasis (Metastasis)
3. Melanoma (Melanoma, Malignant)
4. Neuroendocrine Tumors (Neuroendocrine Tumor)
01/01/2018 - "The PRC methods proposed provide a significant quantitative improvement in [68Ga]DOTA-labeled PET/CT imaging of mice with neuroendocrine tumors, hence demonstrating that these techniques could also ameliorate the deleterious effect of the positron range in clinical PET imaging."
01/01/2018 - "Since generators accessibility has made Ga-68 tracers wide available, the aim of this study is to show how the quantitative results of [68Ga]DOTA-labeled PET/X-ray computed tomography (CT) imaging of neuroendocrine tumors in mice can be improved using positron range correction (PRC). "
01/01/2022 - "This HIPAA-compliant, IRB-approved study with waiver of consent included retrospective imaging review of 180 consecutive patients with neuroendocrine tumors presenting for DOTA PET/CT image acquisition: Ga-68 DOTATATE dose was reported as (0.054 mCi/Kg) scans between September 2018 and May 2019. "
09/01/2019 - "The goal of this study was to verify whether breath-hold [68Ga]DOTA-TOC PET/CT (bhPET) allows detection of additional foci compared to free-breathing PET/CT (fbPET), and to assess the impact of breath-holding on standard uptake values (SUV) and isocontoured volume (Vic40) in patients with neuroendocrine tumors (NET). "
12/10/2018 - "The aim of this study was to evaluate the predictive power of the absorbed dose to kidneys after the first course of treatment with [177Lu]-DOTA-TATE for neuroendocrine tumors (NETs) on the cumulative kidney absorbed dose after 3 or 4 cycles of treatment. "
5. Prostatic Neoplasms (Prostate Cancer)

Related Drugs and Biologics

1. Somatostatin Receptors (Somatostatin Receptor)
2. Peptides (Polypeptides)
3. Radioisotopes (Radionuclides)
4. Chelating Agents
5. 1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)
6. Radiopharmaceuticals
7. Trastuzumab (Herceptin)
8. 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
9. Somatostatin (Somatotropin Release-Inhibiting Factor)
10. Octreotide (Sandostatin)

Related Therapies and Procedures

1. Therapeutics
2. Radioimmunotherapy
3. Radiotherapy
4. Precision Medicine
5. Castration